Cambrex has completed a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex’s flagship API facility by 30%. The expansion positions Cambrex with the largest and most advanced API facility in the U.S. and ensures the long-term capacity to support Cambre...